Ophtec’s Precizon Presbyopic IOL with Continuous Transitional Focus (CTF) Optic Now Patented in the US

Ophtec was granted a patent by the US patent office for its Continuous Transitional Focus (CTF) optical design of the new aspheric presbyopia correcting IOL. This new generation of multifocal IOLs for the treatment of cataracts, called “Precizon Presbyopic,” allows patients to experience a more natural vision at all distances after surgery, according to a company news release.

“Bringing new innovative products to the ophthalmic market is part of Ophtec’s DNA. We are proud to offer a groundbreaking option for patients and surgeons who are looking for alternatives to regular multifocal IOLs”, Tiago Guerreiro, Global Marketing Director at Ophtec, said in the news release.

Precizon Presbyopic enables most patients to perform their daily activities without having to use glasses. Furthermore the lens is designed to be pupil independent and to allow patients to enjoy a better vision at different distances.

Precizon Presbyopic, with the CTF patented technology, has European CE Mark approval and is commercially available across Europe, including The Netherlands, Spain, Portugal, Germany and the UK. South Korea and South Africa also have access to Precizon Presbyopic lenses.

The new IOL is not available in the United States.